CBSC
Cardiac Biotech Solutions Inc., through its international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians. Cardiac Biotech Solutions' wholly owned U.S. subsidiary, My-Cardia (USA), Inc., develops ECG recording device worn by patients in an ambulatory setting for up to 30 days.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | -0.00 | $40,329 | -$182,250 |
| 2025 Q2 | 0.00 | $26,868 | — |
| 2025 Q1 | -0.00 | $45,072 | -$141,065 |
| 2025 Q4 | -0.00 | $6,856 | — |
| 2024 Q3 | -0.00 | $11,801 | -$204,740 |
| 2024 Q2 | -0.00 | $11,162 | -$181,489 |
| 2024 Q1 | -0.00 | $11,578 | -$161,290 |
| 2024 Q4 | -0.00 | $10,416 | -$508,171 |